PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Remarkably, many of these patients are highly responsive to checkpoint blockade treatment (Diaz and Le, 2015; Le et al., 2017; Le et al., 2015) where the tumor infiltrating CD8+ cytotoxic T cells can be reactivated by anti-PD1 antagonists to effectively eradicate tumors.”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Diaz and Le, 2015
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Epitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Cited by
Items 101–200 of 435
Colorectal cancer subtypes: Translation to routine clinical pathology
Roseweir, A. K., McMillan, D. C., Horgan, P. G., & Edwards, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.006 · Cited by 60
BST2 induced macrophage M2 polarization to promote the progression of colorectal cancer
He, X., Chen, H., Zhong, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., Shi, D., & Li, D. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72538 · Cited by 55
Dyer, B. A., Feng, C. H., Eskander, R. N., Sharabi, A. B., Mell, L. K., McHale, M. T., & Mayadev, J. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.016 · Cited by 56
Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma
Yan, G., An, Y., Xu, B., Wang, N., Sun, X., & Sun, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670490 · Cited by 58
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Cai, X., Wei, B., Li, L., Chen, X., Liu, W., Cui, J. T., Lin, Y., Sun, Y., Xu, Q., Guo, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106858 · Cited by 58
Shi, F., Wang, X., Teng, F., Kong, L., & Yu, J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1276133 · Cited by 54
Moretto, R., Rossini, D., Catteau, A., Antoniotti, C., Giordano, M., Boccaccino, A., Ugolini, C., Proietti, A., Conca, V., Kassambara, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006633 · Cited by 51
The Janus Face of Tumor Microenvironment Targeted by Immunotherapy
Buoncervello, M., Gabriele, L., & Toschi, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174320 · Cited by 53
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Gaiser, M. R., Bongiorno, M. A., & Brownell, I. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445966 · Cited by 53
Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer
Chae, Y. K., de Viveiros, P. A. H., Junior, G. L. L., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.016 · Cited by 50
Progress in Neoantigen Targeted Cancer Immunotherapies
Han, X.-J., Ma, X.-L., Yang, L., Wei, Y.-Q., Peng, Y., & Wei, X.-W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00728 · Cited by 47
Li, S., Ji, J., Zhang, Z., Peng, Q., Hao, L., Guo, Y., Zhou, W., Cui, Q., & Shi, X. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03861-0 · Cited by 52
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
CCR5 status and metastatic progression in colorectal cancer
Suarez‐Carmona, M., Chaorentong, P., Kather, J. N., Rothenheber, R., Ahmed, A., Berthel, A., Heinzelmann, A., Moraleda, R. R., Valous, N. A., Koşaloğlu‐Yalçın, Z., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1626193 · Cited by 49
Immunotherapy in Sarcoma: Current Data and Promising Strategies
Wood, G. E., Meyer, C. F., Petitprez, F., & D’Angelo, S. P. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432234 · Cited by 54
Cancer vaccine: learning lessons from immune checkpoint inhibitors
Ye, Z., Qian, Q., Jin, H., & Qian, Q. (2017) · Journal of Cancer · doi:10.7150/jca.20059 · Cited by 51
He, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 48
Wang, Y., Lin, J., Cui, J., Han, T., Jiao, F., Zhuo, M., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14069 · Cited by 49
Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
Lee, K. S., Lee, K., Yun, S., Moon, S., Park, Y., Han, J. H., Kim, C., Lee, H. S., & Choe, G. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2675-6 · Cited by 48
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
Du, J., Gu, J., & Li, J. (2020) · Bioscience Reports · doi:10.1042/bsr20200401 · Cited by 49
Zhang, C., Shen, L., Qi, F., Wang, J., & Luo, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29279 · Cited by 57
“…molecular determinants have been well explored such as programmed death‐ligand‐1 (PD‐L1; Patel & Kurzrock, 2015), DNA mismatch‐repair deficiency (Diaz & Le, 2015; Ekbom, Wicklund‐ Glynn, & Adami, 1996; Le et al., 2015), neoantigen load (Efremova, Finotello, Rieder, & Trajanoski, 2017) and…”
Colorectal Cancer Stem Cells in the Progression to Liver Metastasis
González-Villarreal, C. A., Quiroz-Reyes, A. G., Islas, J. F., & Garza-Treviño, E. N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01511 · Cited by 43
Katz, M. H. G., Petroni, G. R., Bauer, T. W., Reilley, M. J., Wolpin, B. M., Stucky, C., Bekaii‐Saab, T., Elias, R., Merchant, N. B., Costa, A. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007586 · Cited by 41
Neutral Theory and the Somatic Evolution of Cancer
Cannataro, V. L., & Townsend, J. P. (2018) · Molecular Biology and Evolution · doi:10.1093/molbev/msy079 · Cited by 44
“…1980; Kimura 1983) and this effect appears to be the cause not only of the renewed immune response of tumors treated with immune checkpoint inhibitors (Diaz and Le 2015; Rizvi et al. 2015; Schumacher and Cannataro and Townsend . doi:10.1093/molbev/msy079 MBE D ow nloaded from https://academ…”
BackgroundInfluentialGutierrez, M. E., Price, K. S., Lanman, R. B., Nagy, R. J., Shah, I., Mathura, S., Mulcahy, M., Norden, A. D., & Goldberg, S. L. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00274 · Cited by 46
Su, D., Zhang, D., Jin, J., Ying, L., Han, M., Chen, K., Li, B., Wu, J., Xie, Z., Zhang, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12846-7 · Cited by 41
Song, Y., Wang, L., Ran, W., Li, G., Xiao, Y., Wang, X., Zhang, L., & Xing, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00096 · Cited by 43
“In second line treatment, despite the status of the RAS/BRAF gene, immune checkpoint inhibitors are recommended for patients with an MSH status (Diaz and Le, 2015; Overman et al., 2018).”
BackgroundIs immunotherapy in the future of therapeutic management of sarcomas?
Clemente, O., Ottaiano, A., Lorenzo, G. D., Bracigliano, A., Lamia, S., Cannella, L., Pizzolorusso, A., Marzo, M. D., Santorsola, M., Chiara, A. D., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02829-y · Cited by 43
Xie, F., Bai, Y., Yang, X., Long, J., Mao, J., Lin, J., Wang, D., Song, Y., Xun, Z., Huang, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107135 · Cited by 41
Identification of key genes and pathways involved in microsatellite instability in colorectal cancer
Yu, C., Hong, H., Zhang, S., Zong, Y., Ma, J., Lu, A., Sun, J. P., & Zheng, M. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9849 · Cited by 45
Efficacy and safety of nivolumab for metastatic biliary tract cancer
Gou, M., Zhang, Y., Si, H., & Dai, G. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s195537 · Cited by 36
Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System
Xing, J., Ying, H., Ji, L., Gao, Y., Sun, Z., Li, J., Bai, C., Cheng, Y., & Wu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00132 · Cited by 37
Wu, J., Yu, W., Pan, J. G., Jin, S., Gu, W., Gan, H., Zhu, Y., & Ye, D. (2020) · International Journal of Cancer · doi:10.1002/ijc.33324 · Cited by 36
Cholangiocarcinoma: new perspectives for new horizons
Rimini, M., Puzzoni, M., Pedica, F., Silvestris, N., Fornaro, L., Aprile, G., Loi, E., Brunetti, O., Vivaldi, C., Simionato, F., et al. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991313 · Cited by 37
Colorectal cancer, radiotherapy and gut microbiota
Zhang, S., Wang, Q., Zhou, C., Chen, K., Chang, H., Xiao, W., & Gao, Y. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.01.16 · Cited by 36
Zhao, C., Jiang, T., Ju, J. H., Zhang, S., Tao, J., Fu, Y. S., LoCoco, J. S., Dockter, J., Pawlowski, T. L., & Bilke, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.21.349100 · Cited by 53
Mjelle, R., Sjursen, W., Thommesen, L., Sætrom, P., & Hofsli, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5330-0 · Cited by 38
Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma
Luo, Y., Yang, Y., Shen, C., Ma, B., Xu, W., Wang, Q., Zhang, Y., Liao, T., Wei, W., & Wang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.859013 · Cited by 36
Chen, M., Chang, S., Lin, P.-C., Yang, S.-H., Lin, C., Lan, Y., Lin, H., Lin, C., Lai, J., Liang, W.-Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0171 · Cited by 38
Wang, Z., Zhao, X., Gao, C., Gong, J., Wang, X., Gao, J., Li, Z., Wang, J., Yang, B. Y., Wang, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001297 · Cited by 38
Wu, X., Lan, X.-L., Hu, W., Zhang, W., Lai, X., Xu, S., Li, J., Qiu, W., Wang, W., Xiao, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02931-6 · Cited by 37
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Qi, X. (2022) · American Journal of Cancer Research · doi:10.62347/etjh6697 · Cited by 34
Implementing precision cancer medicine in the genomic era
Chen, H., Bonneville, R., & Roychowdhury, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.009 · Cited by 37
The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis
Chen, D., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106966 · Cited by 37
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 35
Liu, Y., Lang, T., Zheng, Z., Cheng, H., Huang, X., Wang, G., Yin, Q., & Li, Y. (2019) · Small · doi:10.1002/smll.201902822 · Cited by 33
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2019) · Aging · doi:10.18632/aging.102349 · Cited by 35
Tan, X., Gong, L., Li, X., Zhang, X., Sun, J., Luo, X., Wang, Q., Chen, J., Xie, L., & Han, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112174 · Cited by 33
A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy
Xu, B., Lu, M., Yan, L., Ge, M., Ren, Y., Wang, R., Shu, Y., Hou, L., & Guo, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796647 · Cited by 42
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
Aprile, G., Negri, F., Giuliani, F., Carlo, E. D., Melisi, D., Simionato, F., Silvestris, N., Brunetti, O., Leone, F., Marino, D., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.025 · Cited by 34
How I treat MSI cancers with advanced disease
Kok, M., Chalabi, M., & Haanen, J. B. A. G. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000511 · Cited by 39
The Ways of Isolating Neoantigen-Specific T Cells
Li, Q., & Ding, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01347 · Cited by 32
Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S.-B., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · BMC Cancer · doi:10.1186/s12885-020-07695-3 · Cited by 38
Hereditary Colorectal Cancer Syndromes: Molecular Genetics and Precision Medicine
Chen, L., Ye, L., & Hu, B. (2022) · Biomedicines · doi:10.3390/biomedicines10123207 · Cited by 37
“Hence, ICIs are being studied as immune-preventive agents in LS [88].”
BackgroundXu, Y., Nowsheen, S., & Deng, M. (2023) · Cancers · doi:10.3390/cancers15051619 · Cited by 33
Building proteomic tool boxes to monitor MHC class I and class II peptides
Schumacher, F., Delamarre, L., Jhunjhunwala, S., Modrusan, Z., Phung, Q. T., Elias, J. E., & Lill, J. R. (2017) · PROTEOMICS · doi:10.1002/pmic.201600061 · Cited by 23
Quezada-Marín, J. I., Lam, A. K.-Y., Ochiai, A., Odze, R. D., Washington, M. K., Fukayama, M., Rugge, M., Klimstra, D. S., Nagtegaal, I. D., Tan, P. H., et al. (2020) · Histopathology · doi:10.1111/his.14120 · Cited by 31
Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
Chen, M., & Wang, S.-L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111717 · Cited by 30
Hu, Q., Shi, Y., Wang, H., Li, B., & Xu, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00627-6 · Cited by 32
Gou, M., Si, H., Yong, Z., Qian, N., Wang, Z., Shi, W., & Dai, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22302-z · Cited by 29
Caracciolo, D., Riillo, C., Arbitrio, M., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33038 · Cited by 32
Wang, J., Zhang, X., Li, J., Ma, X., Feng, F., Liu, L., Wu, J., & Sun, C. (2020) · Aging · doi:10.18632/aging.104204 · Cited by 31
Liu, J., Kong, X., Ping, S., Wang, R., Li, W., & Chen, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16147 · Cited by 32
Garcia‐Vicién, G., Mezheyeuski, A., Bañuls, M., Ruiz-Roig, N., & Molleví, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041544 · Cited by 30
“Studies have demonstrated that patients with MSI-H cancer, which develop distant metastases, may benefit from immunotherapy [95,96].”
Au, T. H., Wang, K., Stenehjem, D. D., & Garrido‐Laguna, I. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.04 · Cited by 32
Yu, S., Li, J., Zhang, J., Zeng, G., Zeng, B., Song, S., Lao, Z., Chen, H., Wen, Z., Yang, Z., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c17090 · Cited by 30
Cai, C., Peng, Y., Shen, E., Wan, R., Gao, L., Gao, Y., Zhou, Y., Huang, Q., Chen, Y., Liu, P., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103866 · Cited by 31
Guo, Y., Liu, Y., Zhang, W., Luo, H., Shu, P., Chen, G., & Li, Y. (2022) · Discover Oncology · doi:10.1007/s12672-022-00466-5 · Cited by 28
Current status and prospect of immunotherapy for colorectal cancer
Yang, W., Zheng, H., Lv, W., & Zhu, Y. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04553-z · Cited by 29
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
Sfakianaki, M., Papadaki, C., Tzardi, M. N., Trypaki, M., Manolakou, S. D., Messaritakis, I., Saridaki, Z., Athanasakis, E., Mavroudis, D., Tsiaoussis, J., et al. (2020) · Cancers · doi:10.3390/cancers12082058 · Cited by 33
Jia, M., Yao, L., Yang, Q., & Chi, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00168 · Cited by 29
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Attalla, K., DiNatale, R. G., Rappold, P. M., Fong, C. J., Sánchez-Vega, F., Silagy, A. W., Weng, S., Coleman, J., Lee, C., Carlo, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4058 · Cited by 29
Yu, Y., Zhu, Y.-J., Xiao, Z., Chen, Y., Chang, X., Liu, Y., Tang, Q., & Zhang, H. (2022) · Biomarker Research · doi:10.1186/s40364-022-00421-0 · Cited by 29
Alam, R., Seo, K. J., Abdul‐Ghafar, J., Yim, K., Lee, S. H., Jang, H., Jung, C. K., & Chong, Y. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad151 · Cited by 28
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value
Battaglin, F., Baca, Y., Millstein, J., Yang, Y., Xiu, J., Arai, H., Wang, J., Ou, F., Innocenti, F., Mumenthaler, S. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007939 · Cited by 29
Basa, R. C. B., Davies, V., Li, X., Murali, B., Shah, J., Yang, B., Shi, L., Khan, M. W., Tian, M., Tejada, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156660 · Cited by 30
Lazarus, J., Oneka, M. D., Barua, S., Maj, T., Lanfranca, M. P., Delrosario, L., Sun, L., Smith, J. J., D'Angelica, M. I., Shia, J., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07508-3 · Cited by 29
Wang, S., Wang, Z., Li, Z., Xu, J., Meng, X., Zhao, Z., & Hou, Y. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201240 · Cited by 28
Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy
Mishra, A., Gupta, K., Kumar, D., Lofland, G., Sharma, A., Sólnes, L. B., Rowe, S. P., Forde, P. M., Pomper, M. G., Gabrielson, E. W., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007535 · Cited by 27
Li, J., Ma, S., Lin, Q., Wang, Q., Zhong, W., Wei, C., Liu, J., Chen, J., Wang, D., Tang, W., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101326 · Cited by 31
Jiang, F., Zhang, H., Yu, C., & Liu, A. (2021) · Neoplasma · doi:10.4149/neo_2021_201228n1415 · Cited by 27
Pira, G., Uva, P., Scanu, A. M., Cossu‐Rocca, P., Murgia, L., Uleri, E., Piu, C., Porcu, A., Carru, C., Manca, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-57311-z · Cited by 29
Stahler, A., Stintzing, S., von Einem, J. C., Westphalen, C. B., Heinrich, K., Krämer, N., Michl, M., Modest, D. P., von Weikersthal, L. F., Decker, T. W., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.003 · Cited by 28
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
Lee, S., & Oh, S. C. (2016) · BioMed Research International · doi:10.1155/2016/7590245 · Cited by 25
Sugiyarto, G., Lau, D., Hill, S. L., Arcia, D., Boulanger, D. S. M., Parkes, E. E., James, E., & Elliott, T. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007114 · Cited by 24
Ye, B., Li, Z., & Wang, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1428529 · Cited by 26
Han, Q., Li, J., Li, Z. Y., Aishajiang, R., & Yu, D. N. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101601 · Cited by 32
“In 2017, the U.S. Food and Drug Administration approved the use of ICIs for treating CRC; however, only 14 % of CRC subtypes, particularly those with mismatch repair deficiencies or microsatellite instability, achieved significant progression-free survival rates [117 – 119].”
Alderdice, M., Craig, S. G., Humphries, M. P., Gilmore, A. R., Johnston, N., Bingham, V., Coyle, V. M., Senevirathne, S., Longley, D. B., Loughrey, M. B., et al. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab016 · Cited by 24
“Recent advances in our understanding of the immune landscape in CRC, coupled with the development of immune-checkpoint therapy has underpinned improved outcomes for a subset of deficient mismatch repair (dMMR) CRC patients (1,2).”
BackgroundGou, M., Zhang, Y., Liu, T., Si, H., Wang, Z., Yan, H., Qian, N., & Dai, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648068 · Cited by 23
Fang, L., Zhao, W., Ye, B., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670313 · Cited by 25
The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer
Liu, C., Qifeng, J., & Shaolei, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01117-7 · Cited by 24
Anderson, K. G., Braun, D. A., Buqué, A., Gitto, S. B., Guerriero, J. L., Horton, B. L., Keenan, B. P., Kim, T. S., Overacre-Delgoffe, A. E., Ruella, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006533 · Cited by 24
Pabla, S., Andreas, J., Lenzo, F. L., Burgher, B., Hagen, J., Giamo, V., Nesline, M., Wang, Y., Gardner, M., Conroy, J. M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27142 · Cited by 21
Whitehair, R. M., Peres, L. C., & Mills, A. M. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000657 · Cited by 21
Cai, C., Long, J., Huang, Q., Han, Y., Peng, Y., Guo, C., Liu, S., Chen, Y., Shen, E., Long, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.615296 · Cited by 24
“Cold” colorectal cancer faces a bottleneck in immunotherapy
Liu, J., Yang, M., Bai, J., Liu, Z., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.240 · Cited by 23
The current status and prospect of immunotherapy in colorectal cancer
Shu, Y., & Zheng, S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03235-0 · Cited by 22
Ye, X., Liu, Y., Wei, L., Sun, Y., Zhang, X., Wang, H., Guo, H., Qin, X., Li, X., Qu, D., et al. (2024) · Advanced Science · doi:10.1002/advs.202405886 · Cited by 21
Jang, M., Kwon, Y., Kim, H., Kim, H., Min, B. S., Park, Y., Kim, T. I., Hong, S. P., & Kim, W. K. (2018) · BMC Cancer · doi:10.1186/s12885-018-5127-6 · Cited by 21
Metadata
- Authors
- Asaoka, Y., Ijichi, H., & Koike, K.
- ORCID
- Hideaki Ijichi
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-12
- Volume
- 373
- Issue
- 20
- Pages
- 1979-1979
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2597802455
- Cited by
- 426
- References
- 3
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 31 · 2023: 52 · 2022: 46 · 2021: 52 · 2020: 60 · 2019: 45 · 2018: 24 · 2017: 30 · 2016: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- anti-PD-1 therapy, mismatch repair deficiency, cancer immunotherapy, immune checkpoint inhibitors, microsatellite instability, Lynch syndrome, tumor immunology
- MeSH terms
- Antineoplastic Agents, Female, Humans, Male, Neoplasm Metastasis, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.